Please assess the completion status of the following clinical trial:

Trial Title: Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed locally advanced or metastatic colorectal cancer~* Measurable or evaluable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST)~* ECOG performance status ≤ 2~* Age 18 - 72 years~* Patients who have had a CR, PR or SD after 1st line therapy based on Irinotecan+Bevacizumab~* Paraffin block from the primary tumor in order to perform tha mutational analysis of the KRAS gene~* Adequate liver (Bilirubin ≤ 1.5 upper normal limit, SGOT/SGPT ≤ 4 upper normal limit, ALP ≤ 2.5 upper normal limit),renal (Creatinine ≤ 1.5 upper normal limit) and bone marrow (ANC ≥ 1,500/mm3, PLT ≥100,000/mm3) function~* Patients must be able to understand the nature of this study~* Written informed consent~Exclusion Criteria:~* Presence of central nervous system or brain metastases~* Pregnant or lactating woman~* Life expectancy \< 3 months~* Previous radiotherapy within the last 4 weeks or \> 25% of bone marrow or in the field where the treatment target is located~* Peripheral neuropathy grade ≥2~* Known hypersensitivity to Erbitux~* Metastatic infiltration of the liver \>50%~* Patients with chronic diarrhea (at least for 3 months) or partial bowel obstruction or total colectomy~* Active infection~* Second primary malignancy, except for non-melanoma skin cancer and in situ cervical cancer~* Psychiatric illness or social situation that would preclude study compliance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 72 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Irinotecan+Erbitux -\> XELOX+Erbitux
- 2 (Type: EXPERIMENTAL): XELOX+Erbitux -\>Irinotecan+Erbitux

Based on this trial design, predict the completion outcome and termination type (if applicable).